Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 536 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 536 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $29.00, for a total transaction of $15,544.00. Following the transaction, the chief operating officer owned 181,641 shares in the company, valued at $5,267,589. This represents a 0.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.29, for a total transaction of $253,625.00.
• On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $23.01, for a total value of $287,625.00.

Bicara Therapeutics Stock Down 2.6%

Shares of NASDAQ:BCAX traded down $0.77 on Friday, reaching $28.91. The company had a trading volume of 584,437 shares, compared to its average volume of 1,011,479. Bicara Therapeutics Inc. has a twelve month low of $9.47 and a twelve month high of $30.99. The stock has a 50-day moving average price of $23.43 and a 200 day moving average price of $20.10. The stock has a market capitalization of $1.90 billion, a P/E ratio of -10.40 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.21). On average, sell-side analysts predict that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BCAX. Bank of America began coverage on shares of Bicara Therapeutics in a research report on Wednesday, March 25th. They issued a “buy” rating and a $35.00 price target on the stock. HC Wainwright upped their price objective on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley raised their target price on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Wells Fargo & Company lifted their target price on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 31st. Finally, Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.27.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Bicara Therapeutics by 596.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after buying an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Bicara Therapeutics in the fourth quarter worth $44,484,000. Vestal Point Capital LP increased its position in Bicara Therapeutics by 80.6% during the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock worth $46,450,000 after acquiring an additional 2,231,025 shares during the period. Franklin Resources Inc. bought a new position in Bicara Therapeutics during the fourth quarter worth $27,265,000. Finally, State Street Corp increased its position in Bicara Therapeutics by 179.5% during the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after acquiring an additional 1,059,260 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.